Novo Nordisk A/S (NVO) 주식 — 좋은 사업일까?

Novo Nordisk A/S (NVO) 주식 — 좋은 사업일까? — InspectStocks

어떻게 돈을 버는가

Sales of prescription medicines for diabetes, obesity and other conditions

경쟁 상대

LLYEli Lilly and Company
A
규모
US$1.36T
이익률
31.9%

무엇을 파는가3

Wegovy injection
An injectable semaglutide medicine used for weight management.
Wegovy pill
A once-daily semaglutide pill used for weight management.
Ozempic
An injectable semaglutide medicine for type 2 diabetes.

누가 사는가3

People with diabetes or obesity who obtain medicines through a prescription or buy them directly in self-pay channels.
Pharmacies and telehealth providers that supply medicines to patients.
Private insurers and public programs that cover prescription medicines, including Medicare Part D in the United States.

무엇에 기대고 있고, 무엇이 무너뜨릴 수 있는가

사업이 기대고 있는 것

1Recent sales growth and product launches rely on glucagon-like peptide-1 (GLP-1) medicines, including semaglutide brands such as Wegovy and Ozempic.
2Access to obesity medicines in the United States depends on insurance coverage and what patients can afford to pay themselves; the company said most Wegovy pill prescriptions there were self-pay in Q2 2026.
3Commercial supply depends on manufacturing capacity; the company said its new active pharmaceutical ingredient facilities were contributing very little commercial supply in Q2 2026.

잘못될 수 있는 일

1Competition and lower realized prices can reduce sales from obesity and diabetes medicines; the company cited intensifying United States competition and pricing pressure in Q2 2026.
2Generic versions of semaglutide can reduce sales where patent protection expires; the company reported early generic entries in some international markets.
3Cybersecurity breaches could disrupt the business.

전체 재무제표 보기 →

Novo Nordisk A/S 소개

Novo Nordisk makes medicines for diabetes and obesity, including Wegovy for weight management and Ozempic for type 2 diabetes. Its medicines reach patients through healthcare providers and pharmacies, with payment coming from insurers and public health programs or directly from patients. It also develops medicines for other conditions, including rare diseases.

본사: Bagsværd, Denmark
설립: 1923
임직원 수: around 66,700 (Q2 2026, medium)
상장 시장: New York Stock Exchange
회계연도 종료: December 31

Novo Nordisk A/S이(가) 미국 증권거래위원회(SEC)에 직접 제출한 공시로 만들었습니다. 수치는 보고된 그대로이며, 주당 이력은 오늘의 주식 수 기준으로 재계산했습니다. 이 기업은 DKK로 공시합니다. 수치는 현재 환율 US$1.00 = 6.7640 DKK로 미국 달러에 환산했으며, 모든 기간에 같은 환율을 적용했습니다. 따라서 성장률과 마진은 환율이 아니라 기업 자신의 것입니다. 이것은 사업을 설명하는 자료입니다. 투자 자문이 아니며 어떤 매수나 매도도 권유하지 않습니다.

Keep exploring

The themes Novo Nordisk A/S is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The themes it is part of

Highest-graded in Drug Manufacturers General

Graded A or B and worth $2B or more: A first, then the largest.

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

어떻게 돈을 버는가

Sales of prescription medicines for diabetes, obesity and other conditions

경쟁 상대

LLYEli Lilly and Company
A
규모
US$1.36T
이익률
31.9%

무엇을 파는가3

Wegovy injection
An injectable semaglutide medicine used for weight management.
Wegovy pill
A once-daily semaglutide pill used for weight management.
Ozempic
An injectable semaglutide medicine for type 2 diabetes.

누가 사는가3

People with diabetes or obesity who obtain medicines through a prescription or buy them directly in self-pay channels.
Pharmacies and telehealth providers that supply medicines to patients.
Private insurers and public programs that cover prescription medicines, including Medicare Part D in the United States.

무엇에 기대고 있고, 무엇이 무너뜨릴 수 있는가

사업이 기대고 있는 것

1Recent sales growth and product launches rely on glucagon-like peptide-1 (GLP-1) medicines, including semaglutide brands such as Wegovy and Ozempic.
2Access to obesity medicines in the United States depends on insurance coverage and what patients can afford to pay themselves; the company said most Wegovy pill prescriptions there were self-pay in Q2 2026.
3Commercial supply depends on manufacturing capacity; the company said its new active pharmaceutical ingredient facilities were contributing very little commercial supply in Q2 2026.

잘못될 수 있는 일

1Competition and lower realized prices can reduce sales from obesity and diabetes medicines; the company cited intensifying United States competition and pricing pressure in Q2 2026.
2Generic versions of semaglutide can reduce sales where patent protection expires; the company reported early generic entries in some international markets.
3Cybersecurity breaches could disrupt the business.

전체 재무제표 보기 →

Novo Nordisk A/S 소개

본사: Bagsværd, Denmark
설립: 1923
임직원 수: around 66,700 (Q2 2026, medium)
상장 시장: New York Stock Exchange
회계연도 종료: December 31

어떻게 돈을 버는가

경쟁 상대

무엇을 파는가3

누가 사는가3

무엇에 기대고 있고, 무엇이 무너뜨릴 수 있는가

사업이 기대고 있는 것

잘못될 수 있는 일

Novo Nordisk A/S 소개

Keep exploring

The themes it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

어떻게 돈을 버는가

경쟁 상대

무엇을 파는가3

누가 사는가3

무엇에 기대고 있고, 무엇이 무너뜨릴 수 있는가

사업이 기대고 있는 것

잘못될 수 있는 일

Novo Nordisk A/S 소개

Novo Nordisk A/S

Keep exploring

The themes it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

Big pharma

성장과 현금 — 5개 중 3개

사업 추세

주가와 등급 추이

어떻게 돈을 버는가

경쟁 상대

무엇을 파는가3

누가 사는가3

무엇에 기대고 있고, 무엇이 무너뜨릴 수 있는가

사업이 기대고 있는 것

잘못될 수 있는 일

Novo Nordisk A/S 소개

Keep exploring

The themes it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

어떻게 돈을 버는가

경쟁 상대

무엇을 파는가3

누가 사는가3

무엇에 기대고 있고, 무엇이 무너뜨릴 수 있는가

사업이 기대고 있는 것

잘못될 수 있는 일

Novo Nordisk A/S 소개

Novo Nordisk A/S

과거 수익률

Keep exploring

The themes it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

Big pharma

성장과 현금 — 5개 중 3개

사업 추세

주가와 등급 추이